Complete Response

Complete Response - most related articles:

- Complete Response Letter on Seroquel XR for major depressive disorder - 4.2
- FDA declines Fusilev NDA for colorectal cancer - 3.8
- Complete response letter for Cinryze for hereditary angioedema - 3.6
- Gardasil approval delayed for use in women ages 27 - 45 - 3.1
- Stress may increase cervical cancer risk - 2.9
- Autism children better at problem solving - 2.6
- New 3 drug combination for multiple myeloma patients - 2.6
- Erivedge approved for skin cancer metastatic basal cell carcinoma - 2.5
- New treatment for melanoma shows shrinking of tumors - 2.2
- New melanoma drug doubles survival of skin cancer patients - 2.2

Complete Response articles

FDA declines Fusilev NDA for colorectal cancer
A Complete Response letter is issued by the U.S. Food and Drug Administration (FDA) regarding the supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for injection for treatment of patients with advanced metastatic colorectal cancer.

Takeda's diabetes drug alogliptin received FDA's objection
US top most health agency FDA has asked Takeda to conduct an additional clinical trial to rule out any adverse effects of alogliptin in relation to heart, that means Takeda needs to conduct a cardiovascular safety trial for alogliptin.

Complete response letter for Cinryze for hereditary angioedema
ViroPharma Incorporated (Nasdaq: VPHM) announced that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) related to its supplemental Biologics License Application (sBLA) for Cinryze(TM) (C1 esterase inhibitor [human]) as a treatment for acute attacks of hereditary angioedema (HAE).

Gardasil approval delayed for use in women ages 27 - 45
Merck & Co., Inc. announced that the U.S. Food and Drug Administration has issued a second complete response letter regarding the supplemental biologics license application (sBLA) for the use of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] in women ages 27 though 45.

Complete Response Letter on Seroquel XR for major depressive disorder
AstraZeneca announced the company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) asking for additional information for the supplemental New Drug Application for SEROQUEL XR (quetiapine fumarate) Extended Release Tablets for the treatment of Major Depressive Disorder (MDD) in adult patients.

5 Complete Response articles listed above.

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
3.76